Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272805
Status:
COMPLETED
Last Update Posted:
2013-02-18
First Post:
2006-01-05
Brief Title:
Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg
Sponsor:
Cardiovascular Clinical Studies
Organization:
Cardiovascular Clinical Studies
Study Overview
Official Title:
Prospective Randomized Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate ReleaseIRon Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day and study patients taking immediate release carvedilol Coreg twice a day
Detailed Description:
Study Further Study Details
Primary outcome pill-taking compliance total doses taken versus total doses prescribed
Expected Total Enrollment 400 subjects at 56 study sites in the US
Study Start October 2005
This is a 5-month double-blind treatment study of male and female subjects with stable mild-to-severe chronic heart failure and with left ventricular dysfunction with symptoms of heart failure
Eligibility
Must be stable on treatment with Coreg IR at a standard dose 625 125 25 mg twice a day
Primary outcome pill-taking compliance total doses taken versus total doses prescribed
Expected Total Enrollment 400 subjects at 56 study sites in the US
Study Start October 2005
This is a 5-month double-blind treatment study of male and female subjects with stable mild-to-severe chronic heart failure and with left ventricular dysfunction with symptoms of heart failure
Eligibility
Must be stable on treatment with Coreg IR at a standard dose 625 125 25 mg twice a day
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CASPER | None | None | None |